Small lymphocytic leukemia

Precursor B-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma Mature (peripheral) B-cell neoplasms B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma... 

Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J.E., and Greco, RA., Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma a phase II trial of the Minnie Pearl Gancer Research Network, /. Clin. Oncol., 21,1746-2751, 2003. 

Flairy-cell leukemia (FICL) is an infrequent B-cell neoplasm characterized by the presence of small lymphocytes with numerous cytoplasmic projections. These cells are found in the peripheral blood and in bone marrow. HCL patients undergoing IFN-a2 therapy may show a decrease in bone marrow inhltration and normalization of peripheral hematologic parameters. More than 85% of patients have objective evidence of partial or complete hematologic response when treated with IFN-a2... 

After validating the database they used the connectivity map to obtain new information they queried the database with expression signatures from patients and animal models to find small molecules that were already in the database that may mimic or suppress particular diseases. In subsequent studies, they identified geduin, an HSP90 inhibitor, as a new lead compound for the treatment of prostate cancer (59) and ra-pamycin as a potential useful drug for treatment of acute lymphocytic leukemia resistant to dexamethasone (60). 

NK cells, monocytes, macrophages, and a small population of granulocytes. Currently, alemtuzumab is approved for the treatment of -cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and have failed fludarabine therapy. Alemtuzumab appears to deplete leukemic and normal cells by direct antibody-dependent lysis. Patients receiving this antibody become lymphopenic and may also become neutropenic, anemic, and thrombocytopenic. As a result patients should be closely monitored for opportunistic infections and hematologic toxicity. 

B cell neoplasms based on morphology, immunophenotype, and genotype often, but not always, correspond to stages of B cell development. However, some B cell lymphomas either do not clearly correspond to a specific developmental stage (i.e., appear to be of variable origin such as chronic lymphocytic leukemia/small lymphocytic lymphoma) or do not appear to be related to any known stage of normal development (i.e., hairy cell leukemia) (H10). 

CLL/SLL, Chronic lymphocytic leukemia/small lymphocytic lymphoma MCL, mantle cell lymphoma FL, follicular lymphoma MZL/MALT, marginal zone lymphoma/mucosa-associated lymphoid tisuse lymphoma SMZL, splenic marginal zone lymphoma HCL, hairy cell leukemia DLCL, diffuse large-cell lymphoma PCM, plasma cell myeloma BCL-1, cyclin D1 FDC MW, Follicular dendritic cell meshworks CK, cytokeratin LELs, lymphoepitheilal lesions. 

D26. Dunphy, C. H., Wheaton, S. E., and Perkins, S. L., CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic tranformations of mantle cell lymphoma. Mod. Pathol. 10, 818-822 (1997). 

K8. Kilo, M. N., and Dorfman, D. M., The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am. J. Clin. Pathol. 105, 451—457 (1996). 

K30. Kroft, S. H., Dawson, D. B., and McKenna, R. W., Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases. Am. J. Clin. Pathol. 115, 385-395 (2001). 

Another small-molecule pan-Bcl-2 inhibitor that mimicks BH3-only proteins, GX15-070 (developed by GeminX, Montreal, Canada) (Fig. 3k), was shown to be a potent apoptosis inducer in breast cancer, chronic lymphocytic leukemia, multiple myeloma, and mantle cell lymphoma cell lines (76-79). 

Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma implications for clinical trials in this patient population. Cancer 2002 94(7) 2033-9. 

Indications Acute lymphocytic leukemia, Non-Hodgkin s lymphoma, Small cell lung cancer Category Antineoplastic Topoisomerase 2 inhibitor Half-life 45 minutes... 

Abbreviations EGF, epidermal growth factor SCLC, small cell lung carcinoma ALL, acute lymphocytic leukemia CML, chronic myelogenous leukemia. 

Brain tumors Carcinoid tumors Chronic lymphocytic leukemia Colorectal cancer Esophageal cancer Head and neck cancers Kaposi s sarcoma Metastatic melanoma Mycosis fungoides Non-small-cell lung cancer Ovarian cancer ... 

ANLL, acute nonleukocytic leukemia ALL, acute lymphocytic leukemia BM, bone marrow CIcr, creatinine clearance CLL, chronic lymphocytic leukemia CML, chronic myelogenous leukemia DNA, deoxyribonucleic acid HD, Hodgkin s disease HSV, herpes simplex virus IT, intrathecal MDS, myelodysplastic syndrome NHL, non-Hodgkin s lymphoma NSCLC, non-small-cell lung cancer PCP, Pneumocystis carinii pneumonia RNA, ribonucleic acid WBC, white blood cells. 

CD25 functions as a low-affinity interleukin-2 receptor and may be found on a number of cell types including activated T cells. This antigen is characteristically expressed on hairy cell leukemia, mast cell lesions, and certain T-cell malignancies but may be seen at low levels in certain B-cell lymphomas, particularly small cell lymphocytic lymphoma/chronic lymphocytic leukemia. Targeted therapy is available for this antigen (Ontak). 

---